An adenovirus (Adv) retaining normal E1A but lacking the 55 kDa E1B protein replicates preferentially in TP53-deficient cancer cells including pancreatic cancer cell lines, resulting in the oncolysis of the tumor. When tumor cells are exposed to hypoxia, hypoxia-inducible factor-1a (HIF-1a) is stabilized and activated to promote the transcription of several genes such as vascular endothelial growth factor (VEGF), but in the presence of E1A hypoxia-induced VEGF m-RNA synthesis is inhibited by E1A binding to p300. In this study, we demonstrated that the cancer cells infected with a mutant Adv in which the p300 binding site in E1A was partially deleted induced a higher expression level of VEGF as compared to those of Adv with normal E1A. An immunoprecipitation study for E1A confirmed that mutant E1A had a reduced binding capacity for p300. Although the expressions of HIF-1a m-RNA were almost the same in both cancer cells infected with the mutant Adv and those with the wild Adv, the amount of HIF-1a protein in cancer cells infected with the wild E1A Adv was lower than in those infected with the mutant E1A type Adv. In vivo, in contrast to the angiogenesis treated with mutant E1A, wild-E1A inhibited tumor angiogenesis significantly. These results suggested that E1A suppressed the production of VEGF and inhibited tumor angiogenesis by binding with p300, resulting in the inhibition of the HIF1a-mediated transcription of genes through binding to HRE. This study demonstrates, for the first time, the effect of an oncolytic replication-competent Adv in inhibiting tumor angiogenesis.
Introduction
Pancreatic carcinoma is the fifth leading cause of death in Japan and the US. 1, 2 The disease remains one of the most difficult cancers to treat; very few effective therapies are available, with surgery being the sole chance for cure. However, surgery is not a viable option for most pancreatic cancer patients. 3 Cancers arise as a result of specific genetic changes in a handful of oncogenes and tumor suppressor genes. Four pivotal molecular events characterize pancreatic ductal adenocarcinoma. These are the activation of KRAS oncogene (more than 80% of cases), and mutational inactivation of the tumor suppressor genes, TP53 (50-70% of patients), MTS1 (more than 80% of patients), and SMAD4 (55% of patients). [4] [5] [6] [7] These genetic alterations are candidate targets for the development of novel therapeutic approaches including virus-mediated gene therapy. 8, 9 Cancer gene therapy can be directed at different components of the tumor biology. A common approach involves restoration of the inactivated tumor suppresser gene function by re-introducing wild-type copies of those genes. This is done with the aim of causing growth suppression or programmed cell death (apoptosis) rather than complete genetic correction. 10, 11 An attractive means of increasing the number of cells transduced in a tumor is to use oncolytic replication-selective adenoviruses (Advs) as therapeutic agents themselves that depend on the transformed phenotype of the tumor cell to replicate. ONYX-015 is a mutant Adv that preferentially replicates in cells lacking functional TP53 (a property of many tumor cells) due to a deletion in the Adv E1B gene. 12, 13 Tumor cell killing occurs in virtue of the general lytic action of the replicating Advs within the cells. The use of ONYX-015 has been proven safe enough to reach Phase III trials.
Several lines of direct evidence show that angiogenesis is essential for the growth and persistence of solid tumors and their metastases. To stimulate angiogenesis, tumors upregulate the production of a variety of angiogenic factors, including vascular endothelial cell growth factor (VEGF). [14] [15] [16] Hypoxia-inducible factor-1 (HIF-1) is a heterodimeric basic helix-loop-helix protein (HIF-1a and HIF1b) 17, 18 that activates the transcription of hypoxiaresponsive genes including VEGF and erythropoietin in hypoxic cells. 19 Several studies have shown an association between HIF-1a expression and human cancer progression. [20] [21] [22] [23] In a separate study, HIF-1a was overexpressed in colon, breast, gastric, lung, skin, ovarian, pancreatic, prostate and renal carcinomas, and associated with cell proliferation. 20, 23 In the presence of oxygen, HIF-1a interacts with the von Hippel-Lindau (VHL) complex. This complex, together with a ubiquitin-activating enzyme (E1), mediates the ubiquitination (Ub) of HIF-1a. The Ub modification targets HIF-1a for proteasomal degradation. 24, 25 In the absence of oxygen, HIF-1a remains stable. Stabilized HIF-1a is translocated to the nucleus, where it interacts with cofactors such as aryl hydrocarbon receptor nuclear translocator (ARNT), CREB binding protein (CBP)/p300 and the DNA polymerase II (Pol II) complex to bind to hypoxiaresponsive elements (HREs) and activate the transcription of target genes. Since the activation of HIF-1 has been associated with a variety of tumors and oncogenic pathways, it is a prime target for anticancer therapies. 19, 20, 26, 27 Cancer cells infected with a replication selective oncolytic Adv such as ONYX-015 express Adv early region 1A (E1A), which is essential for viral replication.
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E1A is a multi-functional protein that binds to several cellular proteins including Rb, 29, 30 p300, 31 and CBP. [32] [33] [34] p300, which is one of the cellular targets for E1A, acts as a transcriptional cofactor in transcriptional activation including that of hypoxia-induced transcription. As previously described, infection with the wild-type Adv inhibits the hypoxia-induced transcription of erythropoietin gene in a p300-dependent manner. The transcription of VEGF is activated by HIF-1 19 as well as erythropoietin. We speculated that replication-selective Advs have an inhibitory effect on tumor angiogenesis through E1A-mediated inhibition of the p300 function. In order to analyze the antiangiogenic effect of the replicating Adv, pancreatic cancer cells were infected with several mutant constructs. In this report, it was demonstrated that the oncolytic replication-selective Adv inhibits the production of VEGF in vitro and neovascularization in vivo. Since oncolytic replication-selective Advs have been developed by several groups, this study supplies important information relating to the E1A region for future projects to develop cancer gene therapy.
Materials and methods

Cell lines
We used four human pancreatic cancer cell lines in these experiments. AsPC-1 and Panc-1, which are well-known cell lines, were purchased from American Types Culture Collection (ATCC, Manassas, VA). The other cell lines, PK-1 and PK-8, were established in our department. 35 All of these cell lines have mutations in the TP53 gene 36 and were maintained in RPMI 1640 medium containing 10% fetal bovine serum, 2 mmol/l L-glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin in a humidified 5% CO 2 atmosphere at 371C.
We used the Anaeropack system (Trial Prodects, Mitsubishi Gas Chemical Co., Tokyo, Japan), which was originally designed for the growth of anaerobic bacteria, to create a hypoxic atmosphere condition in a jar. This system provides a hypoxic atmosphere with about 5% carbon dioxide and less than 1% oxygen within 1 h without the need for evacuation and replacement using an anaerobic atmosphere. 37 
Recombinant Adv
Recombinant Adv containing lacZ gene (AxCA-lacZ) 38 and recombinant Adv lacking E1B55 K (AxE1A dB), an oncolytic replication-competent Adv, 28 were prepared as described previously. Recombinant Adv lacking E1B55 K with mutant E1A in which the p300 binding site at aminoacid sequence position 2-17 was removed (AxdA (2-17) dB) was kindly provided by Dr H Hamada (Department of Molecular Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan). The two recombinant Advs preserve a normal E1B region. dl 1101 contains mutant E1A with the amino-acid sequence at position 4-25 but the p300 binding site was removed. dl 309 is the wild-type Adv, provided by Dr Kirn (Table 1 and Figure 1 ). All Adv vectors were propagated in 293 cells and the titers were determined by a standard plaque assay.
Immunohistochemical staining
AsPC-1 cells were fixed with 1% methanol 24 h after infection of the Adv for the examination of E1A protein and 48 h after infection for the study of hexon protein under both normoxic and hypoxic conditions, and were permeabilized with 0.1% Triton X-100. Immunohistochemical staining of Adv infected cells was performed by the streptavidin-biotin peroxidase method (LSAB kit; DAKO, Kyoto, Japan). Primary antibodies against Adv E1A (mouse monoclonal antibody [M73]; Neo Markers, Fremont, CA) and hexon (mouse monoclonal antibody [Mab] 8051; Chemicon International, Temecula, CA) were applied at 1:100 dilutions, and the cells were incubated for 1 h at room temperature. A biotinyalted goat antimouse secondary antibody was then applied, followed by 
In vitro cell viability in viral infected cells (MTT assay)
In order to evaluate the cell viability of AsPC-1 infected with the Adv vectors, we performed MTT assays. Cells were seeded into 96-well plates at 5 Â 10 3 cells/well and infected with AxCA-lacZ or AxE1A dB or Ax (2-17) dB at a multiplicity of infection (MOI) of 50 and dl 1101 or dl 309 at a MOI of 30. At 24 h after infection, the plate was exposed to a hypoxic condition using an Aneropack system. The medium was changed 0, 24, 48, 72, and 96 h after infection. Sterile tetrazolium salt (10 ml), MTT (3[4, 5-dimethylthiazol-2 yl]-2,5-diphenyl-tetrazolium bromide, Sigma Chemical Co, St Louis, MO) were added to the wells, which were incubated for 4 h at 371C. Finally, 100 ml of 10% SDS were added, and after incubation at 371C overnight, the plate was examined for emmision at 590 nm.
Western blotting and immunoprecipitation of E1A, p300 protein In all, 1 Â 10 7 cells (1 Â 10 8 cells for HIF-1a study) were infected with AxCAlacZ, AxE1A dB, AxdA (2-17) dB, dl 1101 or dl 309, and incubated under normoxia or hypoxia conditions. These cells were lysed in lysis buffer (EBC lysis buffer: 50 mM, HEPES at pH 7.5, 0.15 M NaCl, 1 mM EDTA, 1% NP-40, 1 mM PMSF, 10 mM NaF, 10 ng/ml Leupeptin, 1 mM DTT, and 1 mM sodium vanadate) with protease inhibitor followed by six times of vortex per 1 min, incubation for 5 min on ice and centrifugation at 1500 g for 10 min at 41C. The supernatants were electrophoresed under reducing conditions on 4-20% TrisGlycine Gels and transferred to 0.2 mm Sequi-Blot TM PVDF membrane. The membrane was then blocked for 1 h in blocking buffer (5% skim milk in 1% Tween PBS) and probed with the first antibody (HIF-1a, E1A: mouse monoclonal antibody; BD transduction Laboratories, Pharmingen, p300: rabbit polyclonal antibody; Neo Markers, Fremont, CA) overnight. After being washed, the membrane was incubated with the horseradish peroxidase (HRP)-conjugated IgG second antibody (HIF-1a, E1A: goat anti-mouse, sc-2005, SANTA CRUZE, p300: goat anti-rabbit, sc-2004, SANTA CRUZE) and developed using an enhanced chemiluminescence detection kit (SuperSignal s West Pico Chemiluminescent Substrate, PIERCE). The expression of b-actin was used as the internal control (first antibody: goat polyclonal antibody, I-19, SANTA CRUZE, second antibody: donkey antigoat, sc-2020, SANTA CRUZE).
In the immunoprecipitation study of E1A and p300, AsPC-1 cells, which were infected with various Adv and exposed to hypoxia, were lysed in lysis buffer (EBC lysis buffer, protein inhibitor) and centrifuged. The supernatants, which were previously used for the expression study of E1A and p300, were prepared with E1A antibody (protein: Ab ¼ 200 mg:8 mg) using a Seize TM Classic (G) Immunoprecipitation Kit (Pierce, IL). Samples were heated at 1001C for 5 min, electrophoresed on TrisGlycine Gels and transferred to PVDF membrane. The membrane was then blocked for 1 h in blocking buffer and probed with the p300 first antibody for over night. After being washed, the membrane was incubated with the HRP-conjugated second antibody IgG and developed with the use of an enhanced chemiluminescence detection kit.
ELISA for VEGF
We evaluated the production of VEGF protein and expression in four pancreatic cancer cell lines. 6 Â 10 5 AsPC-1, Panc-1, PK-1, PK-8 cells were plated in 60 mm dishes and infected with AxCA-lacZ, AxE1A dB, AxdA (2-17) dB, dl 1101 or dl 309. The medium was changed 24 h after incubation, and these cells were cultured in normoxic or hypoxic conditions for 24 h and the conditioned medium was collected and centrifuged. The Figure 1 Recombinant Adv. AxE1A dB, which has wild E1A and E1B19K but not E1B55K. AxdA (2-17) dB, which has mutant E1A in which the p300 binding site was partially removed at the amino-acid sequence position 2-17 and E1B19K but not E1B55K. dl 1101, which have mutant E1A in which the p300 binding site was partially removed at the amino-acid sequence position 4-25, E1B19K, and E1B55K. ) were plated in 60 mm dishes and infected with AxCA-lacZ, AxE1A dB, AxdA (2-17) dB, dl 1101 or dl 309. After 24 h incubation, the medium was changed and these cells were cultured in normoxic or hypoxic conditions. The expression of VEGF was assessed by reverse transcription-polymerase chain reaction (RT-PCR). Total cellular RNA was extracted using Rneasy Mini Kit (Qiagen KK, Tokyo, Japan), then 10 ml aliquots were reversed and transcribed using RNeasy H Minus RT (GIBCO BRL Co.), and 1 mg of the resultant cDNA was amplified. For amplification of VEGF-specific cDNAs, a sense primer annealing within exon 1 (5 0 -CCA-TGA-ACT-TTC-TGC-TGT-CTT-3 0 ) and an antisense primer derived from the untranslated region of exon 8 (5 0 -TCG-ATC-CTT-CTG-TAT-CAG-TCT-3 0 ) were used in a reaction involving denaturation at 941C for 30 s, annealing at 551C for 30 s, and elongation at 721C for 45 s. 39 The number of cycles was 30.
Primers for HIF-1a were constructed as follows: sense primer, . 40 Subsequently, aliquots of 10 ml from the amplification reactions were electrophoresed on 2% agarose (FMC BioProducts, Rokland, ME) Tris-acetate EDTA gels and autoradiographed. 40 Subcutaneous tumor model AsPC-1 cells infected with AxCA-lacZ, AxE1A dB, or dl 1101 were collected and injected into the flank of severe combined immunodeficient mice (6-8 W male, Fox Chase C.B-17/Icr-severe-combined immunodeficient (SCID) Jcl). Subcutaneous tumors and skin of the back were harvested 7 days after inoculation. The picture of the skin of the back was taken using a NICON F3 for the analysis of tumor angiogenesis. Subcutaneous tumors were histologically studied by hematoxylin-eosin staining or immunostaining with rat anti-mouse PECAM-1 (CD 31) antibody (BD pharmingen, San Diego, CA) for detection of endothelial cells in tumor tissue, as described, 40, 41 and E1A antibody and hexon antibody for the detection of Adv. Capillaries (diametero10 mm) of tissue sections were counted in 400 high fields per section using a microscope.
Imaging analysis
Results of one-dimensional electrophoretic gel, such as Western blotting or RT-PCR, were analysed by NIH Image. The data of b-actin and MSH 2 were used as control value, then the ratio of each band to the control band was obtained for comparison.
Data presentation and statistical analysis
Results are presented as mean7standard deviation (s.d.). Statistical analysis was performed by two-tailed Student's t-test using Statview software and Po0.05 was considered to be statistically significant.
Results
Expression of adenoviral proteins in viral infected cells
As viruses have differences in cytotoxicity, the expression of E1A and the replication of viruses were examined by immunohistological staining. AxE1A dB, Ax (2-17) dB infected at a MOI of 50 showed a similar tendency in staining to those of dl 1101 and dl 309 infected at a MOI of 30 (data not shown). Therefore, we use these levels of MOI for AxE1A dB, Ax (2-17) dB, dl 1101 and dl 309 in the following experiments.
In vitro cell viability in viral infected cells
To determine the cell viability of Adv infected AsPC-1, cells were infected with AxE1A dB or Ax (2-17) dB at a MOI of 50, and dl 1101 or dl 309 at a MOI of 30. All types of AsPC-1 cells grew rapidly during 48 h (exposed to hypoxia after 24 h) after infection and grew less rapidly after 72 h (exposed to hypoxia after 48 h). Therefore, we performed all examinations in vitro until 48 h after infection (exposed to hypoxia after 24 h) (Figure 2 ).
VEGF expression in pancreatic cancer cell lines
We measured the level of VEGF in the supernatant of four pancreatic cancer cell lines infected with AxCA-lacZ or AxE1A dB in the normoxic and hypoxic condition using human VEGF-specific ELISA. In the normoxic condition, the values of VEGF in AxE1A dB infected cells were suppressed in a MOI-dependent manner (data not shown). In AsPC-1, PK-8, and PK-1, AxCA-lacZ infected cells showed higher levels of VEGF protein in the hypoxic condition as compared with the normoxic condition. The levels of VEGF protein were significantly decreased in all AxE1A dB infected cell lines as compared to corresponding cell lines infected with AxCA-lacZ (Figure 3a) . The expression of VEGF at the messenger level was measured in four pancreatic cancer cell lines infected with AxCAlacZ or AxE1A dB in both normoxic and hypoxic conditions by RT-PCR. The levels of MSH2 were not affected by hypoxic condition. All cell lines expressed VEGF m-RNA in both conditions and the levels of VEGF expression in AxCA-lacZ infected cells were stronger in the hypoxic condition as compared with those in the normoxic condition or AxE1A dB infected cells in the hypoxic condition (Figure 3b ). These results suggested that this inhibitory effect appeared mainly at the m-RNA level. Under the hypoxic condition, AsPC-1 infected with AxdA (2-17) dB, which has a partial deletion of the p300 binding site in E1A, showed four times higher values of VEGF protein as compared to those of AsPC-1 infected with AxE1A dB (AsPC-1/AxE1A dB) or AsPC-1 with dl 309 (AsPC-1/dl 309) in ELISA (Figure 3c ). AsPC-1 infected with dl 1101 possessing a partial deletion of the p300 binding site in E1A showed five times higher values of VEGF protein than those of AsPC-1/AxE1A dB or AsPC-1/dl 309, however both values were lower than those of AsPC-1 infected with AxCA-lacZ. Similarly, the expression levels of VEGF m-RNA in AsPC-1/Ax (2-17) dB and AsPC-1/dl 1101 in the hypoxic condition were higher than those of AsPC-1/AxE1A dB and AsPC-1/dl 309, but lower than those of AsPC-1/AxCA-lacZ (Figure 3c ).
Western blotting and immunoprecipitation of E1A, p300 protein
The levels of p300 expression were similar among AsPC-1 cells infected with various kinds of viruses during 48 h under the hypoxic condition for 24 h (Figure 4a ). The strong expression of E1A was confirmed by Western blotting in AsPC-1/AxE1A dB, AsPC-1/Ax (2-17) dB, AsPC-1/dl 1101, and AsPC-1/dl 309 but there was no expression in wild AsPC-1 and AsPC-1/AxCA-lacZ.
These samples were immunoprecipitated by the E1A antibody and were analyzed by immunoblotting with the p300 antibody. Although AsPC-1 infected with AxCAlacZ, which has no E1A region, showed no expression of p300, AsPC-1/AxE1A dB, and AsPC-1/dl 309 showed strong expression of p300 as same as levels of nonimmunoprecipitation in wild AsPC-1. The expression levels of p300 in AsPC-1/AxdA (2-17) dB and AsPC-1/dl 1101 were reduced as compared with AsPC-1/AxE1A dB and AsPC-1/dl 309, respectively (Figure 4b) .
These results indicated that E1A of AxdA (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) and dl 1101 with the partial deletion of the p300 binding site showed reduced binding capacity to p300, and a weaker inhibitory effect on VEGF expression in the hypoxic condition as compared to wild E1A binding to p300.
HIF-1a expression of pancreatic cancer cell lines
Four pancreatic cancer cell lines expressed various but high levels of HIF-1a protein in the hypoxic condition as compared with normoxic condition (Figure 5a ), and two of theses cell lines, AsPC-1 and Panc-1, showed levels consistent with those of a previous report. 20 HIF-1a protein was increased under the hypoxic condition, however, those of AsPC-1/AxE1A dB and AsPC-1/dl 309 were not increased as compared with wild AsPC-1, AsPC-1/AxCA-lacZ, but AsPC-1/dl 1101 showed almost the same levels as AsPC-1/AxCA-lacZ (Figure 5b) .
We checked the expression of HIF-1a m-RNA in four pancreatic cancer cell lines. PK-8 showed higher expression of HIF-1a m-RNA as compared with other cell lines, but no cell lines showed an increase in the HIF-1a levels under the hypoxic condition (Figure 6a ). AsPC-1 cells infected with the various Adv expressed HIF-1a m-RNA in the same manner (Figure 6b ). These results suggest that E1A binding to p300 may play some role in the degradation of HIF-1a protein under the hypoxic condition.
Angiogenesis of subcutaneous tumors
Angiogenesis of the flank skin in AsPC-1/AxE1A dB was significantly inhibited (Figure 7 ) as compared to that in AsPC-1/dl 1101 and AsPC-1/AxCA-lacZ.
AsPC-1/AxE1A dB showed a similar staining level to that of AsPC-1/dl 1101 (Figure 8a ) in the immunohistochemical staining of E1A and hexon antibody, but the microvessel count of AsPC-1/AxE1A dB was significantly reduced compared to that of AsPC-1/dl 1101 in the immunohistochemical staining of CD 31 antibody (Po0.05) (Figure 8b and c) .
These results suggested that E1A inhibited tumor angiogenesis in vivo and that there was no significant difference in the function of viral replication between AxE1A dB and dl 1101. Therefore, it is speculated that the stronger antiangiogenesis effect of AxE1A dB resulted from the binding capacity between E1A and p300, thereby interfering with the HIF-1a function under the hypoxic condition. Figure 2 In vitro cell viability in viral infected cells. Adv infected AsPC-1 cells were not infected or infected with either AxCA-lacZ, AxE1A dB and Ax (2-17) dB, dl 1101 and dl 309. All infected AsPC-1 cells grew rapidly after 48 h (exposed to hypoxia after 24 h) and grew less rapidly after 72 h (exposed to hypoxia after 48 h).
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Discussion
In this study, we demonstrated that the expression of E1A in the oncolytic Adv strongly suppressed the production of VEGF at the m-RNA level followed by the inhibition of tumor angiogenesis. It is also suggested that this inhibitory effect required the binding of E1A to p300 protein, resulting in the inhibition of the HIF-1a-mediated transcription of genes through binding to HRE (Figures 3a-c and 4a ). Hypoxia is a common feature of solid tumors and results in the constitutive induction of HIF production. 21, 22 Activation of hypoxia-responsive signaling induces the expression of proangiogenic factors such as VEGF and erythropoietin 19, 26 and establishes a favorable environment for tumor angiogenesis, thereby promoting tumor progression. Since antiangiogenesis gene therapy was demonstrated to be a potent strategy for treating pancreatic cancer, 42 inhibition of HIF-mediated gene expression may be an attractive therapeutic strategy for pancreatic cancer. It has been reported that a dominant negative peptide attenuated the hypoxia-responsive gene expression and inhibited tumor growth in vivo by disrupting the binding between HIF and p300. 43 HIF-1, which is a transcription factor composed of HIF-1a and HIF-1b subunits, 17, 18 is stabilized and Antiangiogenesis effect of oncolytic adenovirus Y Saito et al activated to promote the transcription of VEGF 19 in a hypoxic condition. This condition stimulates the formation of a DNA binding complex containing both HIF-1a, HIF-1b, and p300/CBP. E1A is a poorly understood multifunctional viral protein. It has been speculated that E1A inhibits the function of p300. Arany et al. 19 reported that E1A inhibited the HIF-mediated transcription of erythropoietin gene through the disruption of the HIF/ p300 complex using a luciferase assay. The present study demonstrated that E1A with a partial mutation in the p300-binding site could not decrease the level of VEGF under the hypoxic condition by using ELISA and RT-PCR (Figure 3c) , and that these responses required the binding of E1A and p300 protein by an immunoprecipitation assay (Figure 4b ). These results are compatible with the study by Arany et al., 19 reporting that the transcription of VEGF is controlled by the HIF/p300 complex. In two cell lines, Panc-1 and PK-1, the expression of E1A suppressed the production of VEGF protein in the hypoxic condition as compared with that in the normoxic condition. This result suggests that some mechanism besides the binding of E1A and p300 may exist.
These results, for the first time, demonstrated that wild E1A suppresses the increase of HIF-1a protein under a hypoxic condition and that these responses may require the binding of E1A and p300 protein. A recent report demonstrated that the product of the VHL tumor suppressor gene, which has two tightly coupled domains consisting of an B100 amino-acid b sandwich (b-domain), and an B35-amino-acid three helix cluster (a-domain), 44, 45 mediated the ubiquitination and proteasomal degradation of HIF-1a. 24, 25 The function of the ubiquitination of HIF required both an intact b-domain and an intact a-domain. The b-domain binds directly to HIF-1a and HIF-2a, whereas the a-domain binds to elongin C, which in turn nucleates a complex that contains elongin B, Cullin-2 (Cul2) and Rbx1/Roc1, and may contain further proteins. The results of the present study strongly suggested that E1A could play an important role in the degradation of HIF-1a protein under a hypoxic condition in addition to the inhibitory effect on HIF/p300 complex formation.
Oncolytic replication-competent Advs including ONYX-015 (large E1B-attenuated Adv) 12, 13 are promising tools for cancer gene therapy. High response rates were seen in patients with recurrent head and neck cancer treated with the virus 46 and a Phase II trial for metastatic liver tumor was reported. 47 The main mechanism of the antitumor effect of the virus is thought to be virusinduced cytolysis. Considering the clinical result that ONYX-015 worked synergistically with chemotherapeutic agents 46 and a recent report demonstrating that the CR2 domain of E1A is required for apoptosis, 48 a second mechanism of action could be its action as a chemosensitizer. In addition to these mechanisms, the present study indicated another advantage of the replicationcompetent Adv, namely that it inhibited the tumor angiogenesis. The attenuation of E1B55 K, which is linked to the selectivity of the virus, did not affect the virus-mediated E1A action (Figures 7, 8b and c) . The antiangiogenesis effect through the disruption of HIF/ p300 by E1A might be a third mechanism of the virusmediated antitumor activity. It would be important to assess the inhibitory effect on tumor angiogenesis in the clinical use of the virus. As we previously described, the E1B mutant virus did replicate in pancreatic cancer cells in vitro and inhibited the tumor growth in vivo. 28, 49, 50 These data strongly suggested that the oncolytic replication-competent Adv is a promising tool for gene therapy against pancreatic cancer.
